The Active Components of Fuzheng Huayu Formula and Their Potential Mechanism of Action in Inhibiting the Hepatic Stellate Cells Viability – A Network Pharmacology and Transcriptomics Approach

doi:10.3389/fphar.2018.00525

PMC full text:

Front Pharmacol. 2018; 9: 525.

Published online 2018 May 24. doi: 10.3389/fphar.2018.00525

Copyright/LicenseRequest permission to reuse: Copyright © 2018 Xing, Chen, Li, Cao, Chen, Wang and Zhu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

<< PrevFIGURE 6Next >>

FIGURE 6

An external file that holds a picture, illustration, etc.
Object name is fphar-09-00525-g006.jpg

Active components in FZHY inhibited human HSC-LX-2 activation. LX-2 cells were treated for 24 h with indicated concentrations of (A) schisantherin A, (B) schisandrin B, (C) salvianolic acid A, (D) salvianolic acid B, (E) tanshinone II-A, (F) dihydrotanshinone I, (G) kaempferol. CCK8 assay was used to measure the cell viability. Data were obtained from three independent experiments performed in triplicate and presented as means (±SD). P < 0.05, P < 0.01, P < 0.001 versus the control (CTL).

FIGURE 6

Images in this article

Click on the image to see a larger version.